Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Penile Cancer—Novel Translational and Clinical Insights
share announcement

Penile Cancer—Novel Translational and Clinical Insights

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 12171

Special Issue Editor

Prof. Dr. Igor Tsaur

E-Mail Website
Guest Editor
Department and Outpatient Clinic for Urology and Pediatric Urology, University Medical Center of Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany
Interests: prostate cancer; penile cancer; robot-assisted surgery; translational research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Notwithstanding the great efforts to better understand and characterize the disease as well as improve patient outcomes, successful individualized management of penile cancer is still challenging. In particular, the response rate to available systemic treatment as well as the survival of metastasized patients has remained unchanged for a long time. Obviously, the rarity of penile cancer creates a diagnostic and therapeutic challenge for physicians. The lack of high-level evidence frequently results in a limited guideline adherence and outcomes, especially in nonspecialized centres. Of note, clinical studies are scarce due to the rarity of this condition and the subsequent shortcoming of the support by the pharmaceutical industry and other third parties. In concert, fund raising for translational research is intricate, resulting in a lack of biomarker and targeted therapy candidates, available cell cultures, and xenograft models.

The Special Issue of the Journal of Clinical Medicine entitled “Penile Cancer—Novel Translational and Clinical Insights” is aimed at illuminating of the current outstanding preclinical and clinical research presenting cutting-edge findings in the whole area of this demanding yet intriguing condition. Original as well as review manuscripts of the highest quality are welcomed for submission.

Prof. Dr. Igor Tsaur
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Penile cancer
  • Molecular pathways
  • Genomic alterations
  • Chemotherapy
  • Targeted therapy
  • Biomarker
  • Inguinal lymphadenectomy
  • Sentinel
  • Organ-preserving surgery

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

12 pages, 510 KiB  
Review
Is There an Oncological Benefit of Performing Bilateral Pelvic Lymph Node Dissection in Patients with Penile Cancer and Inguinal Lymph Node Metastasis?
by Rodrigo Suarez-Ibarrola, Mario Basulto-Martinez, August Sigle, Mohammad Abufaraj, Christian Gratzke and Arkadiusz Miernik
J. Clin. Med. 2021, 10(4), 754; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm10040754 - 13 Feb 2021
Cited by 3 | Viewed by 1751
Abstract
We aim to review the literature for studies investigating the oncological outcomes of patients with penile cancer (PC) undergoing bilateral pelvic lymph node dissection (PLND) in the presence of inguinal lymph node metastasis (LNM) who are at risk of harboring pelvic metastasis. A [...] Read more.
We aim to review the literature for studies investigating the oncological outcomes of patients with penile cancer (PC) undergoing bilateral pelvic lymph node dissection (PLND) in the presence of inguinal lymph node metastasis (LNM) who are at risk of harboring pelvic metastasis. A search of English language literature was performed using the PubMed-MEDLINE database up to 3 December 2020 to identify articles addressing bilateral PLND in PC patients. Eight articles investigating bilateral PLND met our inclusion criteria. Patients with pelvic LNM have a dismal prognosis and, therefore, PLND has an important role in both the staging and treatment of PC patients. Ipsilateral PLND is recommended in the presence of ≥2 positive inguinal nodes and/or extranodal extension (ENE). Significant survival improvements were observed with a higher pelvic lymph node yield, in patients with pN2 disease, and in men treated with bilateral PLND as opposed to ipsilateral PLND. Nevertheless, the role of bilateral PLND for unilateral inguinal LNM remains unclear. Although the EAU guidelines state that pelvic nodal disease does not occur without ipsilateral inguinal LNM, metastatic spread from one inguinal side to the contralateral pelvic side has been reported in a number of studies. Further studies are needed to clarify the disseminative pattern of LNM, in order to establish PLND templates according to patients’ risk profiles and to investigate the benefit of performing bilateral PLND for unilateral inguinal disease. Full article
(This article belongs to the Special Issue Penile Cancer—Novel Translational and Clinical Insights)
►▼ Show Figures

Figure 1

17 pages, 681 KiB  
Review
The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy
by Mohamed E. Ahmed, Shayan Falasiri, Ali Hajiran, Jad Chahoud and Philippe E. Spiess
J. Clin. Med. 2020, 9(10), 3334; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm9103334 - 17 Oct 2020
Cited by 23 | Viewed by 3170
Abstract
Penile cancer is an extremely rare malignancy that accounts for approximately 1% of cancer deaths in the United States every year. While primary penile cancer can be managed surgically, advanced and metastatic forms of the disease require more aggressive management plans with systemic [...] Read more.
Penile cancer is an extremely rare malignancy that accounts for approximately 1% of cancer deaths in the United States every year. While primary penile cancer can be managed surgically, advanced and metastatic forms of the disease require more aggressive management plans with systemic chemotherapy and/or radiotherapy. Despite the meaningful response to systemic treatments, the 2-year progression-free survival and disease-specific survival have shown disappointing results. Therefore, there is a crucial need for alternative treatment options with more favorable outcomes and a lower toxicity profile. There are currently extensive studies of tumor molecular biology and clinical trials with targeted molecular therapies, such as PD-1, PD-L1, and CTLA-4. In this review, we will describe the penile cancer microenvironment, and summarize the rationale for immunotherapy in penile cancer patients. Full article
(This article belongs to the Special Issue Penile Cancer—Novel Translational and Clinical Insights)
►▼ Show Figures

Figure 1

15 pages, 5789 KiB  
Review
Utility of Minimally Invasive Technology for Inguinal Lymph Node Dissection in Penile Cancer
by Reza Nabavizadeh, Benjamin Petrinec, Andrea Necchi, Igor Tsaur, Maarten Albersen and Viraj Master
J. Clin. Med. 2020, 9(8), 2501; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm9082501 - 03 Aug 2020
Cited by 9 | Viewed by 6680
Abstract
Our aim is to review the benefits as well as techniques, surgical outcomes, and complications of minimally invasive inguinal lymph node dissection (ILND) for penile cancer. The PubMed, Wiley Online Library, and Science Direct databases were reviewed in March 2020 for relevant studies [...] Read more.
Our aim is to review the benefits as well as techniques, surgical outcomes, and complications of minimally invasive inguinal lymph node dissection (ILND) for penile cancer. The PubMed, Wiley Online Library, and Science Direct databases were reviewed in March 2020 for relevant studies limited to those published in English and within 2000–2020. Thirty-one articles describing minimally invasive ILND were identified for review. ILND has an important role in both staging and treatment of penile cancer. Minimally invasive technologies have been utilized to perform ILND in penile cancer patients with non-palpable inguinal lymph nodes and intermediate to high-risk primary tumors or patients with unilateral palpable non-fixed inguinal lymph nodes measuring less than 4 cm, including videoscopic endoscopic inguinal lymphadenectomy (VEIL) and robotic videoscopic endoscopic inguinal lymphadenectomy (RVEIL). Current data suggest that VEIL and RVEIL are feasible and safe with minimal intra-operative complications. Perhaps the strongest appeal for the use of minimally-invasive approaches is their faster post-operative recovery and less post-operative complications. As a result, patients can tolerate this procedure better and surgeons can offer surgery to patients who otherwise would not be a candidate or personally willing to undergo surgery. When compared to open technique, VEIL and RVEIL have similar dissected nodal count, a surrogate metric for oncological adequacy, and a none-inferior inguinal recurrence rate. Larger randomized studies are encouraged to investigate long-term outcome and survival rates using these minimally-invasive techniques for ILND. Full article
(This article belongs to the Special Issue Penile Cancer—Novel Translational and Clinical Insights)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop